

Without staining
P6
P3
2nd antibody only
P6
P3
SSEA-3
P6
P3
2.0%
50
100
150
200
250
10^2
10^3
10^4
10^5

Fig. 1A



□: M-cluster
■: Muse
□: non-Muse
Relative expressions of mRNA
100
10
1
0.1
*
*
**
**
***
***
OCT4
SOX2
Nanog

Fig.1B




Fig. 1C




Fig. 1D



160
140
120
100
80
60
40
20
0
Cell number/field (200x)
***
***
***
***
**
■: Muse
□: non-Muse
Serum
intact
1 h
24h
48h
Time from CCl_4 injection

Fig. 2A



200
180
160
140
120
100
80
60
40
20
0
Cell number/field (200x)
***
***
***
*
■: Muse
□: non-Muse
Tissue
intact
1 h
24h
48h
Time from CCl_4 injection

Fig. 2B



Intact mouse
■: Muse
□: non-Muse
Relative expressions of genomic DNA
1
0.5
0
0.344
0.307
brain
heart
lung
liver
spleen
pancreas
kidney
muscle
BM
CCl4-treated mouse
■: Muse
□: non-Muse
Relative expressions of genomic DNA
1
0.5
0
0.956
0.346
0.215
brain
heart
lung
liver
spleen
pancreas
kidney
muscle
BM

Fig. 3A



Muse Group
non-Muse Group

Fig. 3B



H-Golgi (+)/total cell/mm² (%)
3
2.5
2
1.5
1
0.5
0
***
Muse
non-Muse

Fig. 3C




Fig. 3D




Fig. 3E




Fig. 4A



***
***
***
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0
Total bilirubin (mg/dl)
Muse
Vehicle
non-Muse

Fig. 4B



**
***
**
3.2
3.1
3
2.9
2.8
2.7
2.6
2.5
2.4
Albumin (g/dl)
Muse
Vehicle
non-Muse

Fig. 4C



Muse Group
Vehicle Group
non-Muse Group
(%)
***
***
***
3.5
3
2.5
2
1.5
1
0.5
0
Muse
Vehicle
non-Muse

Fig. 4D



Muse Group
Vehicle Group
non-Muse Group
(%)
**
***
***
2.5
2
1.5
1
0.5
0
Muse
Vehicle
non-Muse

Fig. 4E




Fig. 5A




Fig. 5B




Fig. 5C




Fig. 5D




Fig. 5E




Fig. 6A



Human liver
Muse
non-Muse
Vehicle
Human Albumin
Human CYP1A2
Human Glc-6-Pase
Human b-actin
Mouse b-actin

Fig. 6B



p<0.05
p<0.001
Skin collagen (μg/mm2 skin)
60
50
40
30
20
10
0
Control group
BLM 28 day+ Vehicle-treated group
BLM 28 day +Muse-treated group

Fig. 7



p<0.05
p<0.0001
Relative dermal thickness
2.5
2.0
1.5
1.0
0.5
0.0
Control group
BLM 28 day + Vehicle-treated group
BLM 28 day + Muse-treated group

Fig. 8



Control group
ID: 106
BLM 28 day+
Vehicle-treated group
ID: 208
BLM 28 day
+Muse-treated group
ID: 305

Fig. 9




All Lobes
All lobes (Vehicle)
All lobes (Muse)
Fibrosis Score (All lobes)
10.0
9.0
8.0
7.0
6.0
5.0
4.0
3.0
2.0
1.0
0.0
Day 21
Day 35
Left Lobe
Left lobe (Vehicle)
Left lobe (Muse)
Fibrosis Score
4.0
3.0
2.0
1.0
0.0
Day 21
Day 35

Fig. 10







Fig. 11



(†: $p<0.05$, ††: $p<0.01$).

Fig. 12